Johnson & Johnson: Chronic Pain trials

The registry lists 23 Chronic Pain studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 1Phase 2 4Phase 3 13Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant PainCompletedNCT01816243Phase 4Results posted
• A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic NeuralgiaCompletedNCT01124617Phase 2Results posted
• An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain ParticipantsCompletedNCT01124604Phase 2Results posted
• A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back PainCompletedNCT01008618Phase 3Results posted
• An Efficacy and Safety Study of Fentanyl in Participants With Chronic PainCompletedNCT00788372Phase 3Results posted
• A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic PainCompletedNCT00736957Phase 3Results posted
• An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic PainCompletedNCT00736853Phase 3Results posted
• An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic PainCompletedNCT00487435Phase 3Results posted
• Tapentadol (CG5503)CompletedNCT00421928Phase 3Results posted
• A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic PainCompletedNCT00361504Phase 3Results posted
• Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic PainCompletedNCT01902524Phase 4
• A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and AcetaminophenCompletedNCT01819805
• The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal AchievementCompletedNCT01688583
• A Study of JNS020QD in Patients With Chronic PainCompletedNCT01493245Phase 3
• Impact of Tolerability Issues on Chronic PainCompletedNCT01484301
• Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee OsteoarthritisCompletedNCT00745069Phase 2
• A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid TolerantCompletedNCT00650182Phase 2
• Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic PainCompletedNCT00410943Phase 3
• A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic PainCompletedNCT00410878Phase 1
• A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic PainCompletedNCT00364546Phase 3
• A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief TherapyCompletedNCT00271466Phase 3
• A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief TherapyCompletedNCT00271453Phase 3
• A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief TherapyCompletedNCT00271414Phase 3